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Abstract
The ability of pathogens to cause disease depends on their aptitude to escape the immune
system. Type IV pili are extracellular filamentous virulence factors composed of pilin mono-
mers and frequently expressed by bacterial pathogens. As such they are major targets for
the host immune system. In the human pathogen Neisseria meningitidis, strains expressing
class I pilins contain a genetic recombination system that promotes variation of the pilin
sequence and is thought to aid immune escape. However, numerous hypervirulent clinical
isolates express class II pilins that lack this property. This raises the question of how they
evade immunity targeting type IV pili. As glycosylation is a possible source of antigenic vari-
ation it was investigated using top-down mass spectrometry to provide the highest molecu-
lar precision on the modified proteins. Unlike class I pilins that carry a single glycan, we
found that class II pilins display up to 5 glycosylation sites per monomer on the pilus surface.
Swapping of pilin class and genetic background shows that the pilin primary structure deter-
mines multisite glycosylation while the genetic background determines the nature of the gly-
cans. Absence of glycosylation in class II pilins affects pilus biogenesis or enhances pilus-
dependent aggregation in a strain specific fashion highlighting the extensive functional
impact of multisite glycosylation. Finally, molecular modeling shows that glycans cover the
surface of class II pilins and strongly decrease antibody access to the polypeptide chain.
This strongly supports a model where strains expressing class II pilins evade the immune
system by changing their sugar structure rather than pilin primary structure. Overall these
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results show that sequence invariable class II pilins are cloaked in glycans with extensive
functional and immunological consequences.
Author Summary
During infection pathogens and their host engage in a series of measures and counter-mea-
sures to promote their own survival: pathogens express virulence factors, the immune sys-
tem targets these surface structures and pathogens modify them to evade detection. Like
numerous bacterial pathogens,Neisseria meningitidis express type IV pili, long filamentous
adhesive structures composed of pilins. Intriguingly the amino acid sequences of pilins from
most hypervirulent strains do not vary, raising the question of how they evade the immune
system. This study shows that the pilus structure is completely coated with sugars thus limit-
ing access of antibodies to the pilin polypeptide chain. We propose that multisite glycosyla-
tion and thus variation in the type of sugar mediates immune evasion in these strains.
Introduction
Members of the Neisseria genus are Gram-negative proteobacteria that include several com-
mensals such as N. sicca, N. lactamica or N. elongata and two human pathogens, N. gonorrheae
and N.meningitidis. Both of these are highly adapted for interaction with humans, their unique
host. N. gonorrheae colonizes the human urogenital tract and is responsible for a sexually trans-
mitted infection characterized by a massive inflammatory response and purulent discharge.
Neisseria meningitis is responsible for devastating sepsis and meningitis [1]. N.meningitidis
proliferates on the surface of epithelial cells lining the nasopharynx in approximately 5 to 30%
of the total human population. Pathogenesis is initiated when bacteria access the bloodstream
from the throat, survive and multiply in the blood. Systemic infection and perturbation of vas-
cular function lead to sepsis, the most severe form of the disease associated with organ dysfunc-
tion, limb necrosis and death in certain cases. N.meningitidis can also cross the blood-brain
barrier and access the cerebrospinal fluid, leading to meningitis.
Type IV pili (Tfp) are extracellular filamentous organelles that can be found on a large num-
ber of bacterial species [2]. In the case of Neisseria spp. they are key virulence factors. These
abundant structures are 6–8 nm wide, can measure several microns in length and are expressed
by all pathogenic Neisseria spp. strains. Type IV pili are primarily composed of a single protein
or major pilin, called PilE in Neisseria spp., which is assembled in a polymeric helical fiber. Neis-
seria type IV pilins have been grouped in two classes (class I and class II) based on the recogni-
tion of the SM1 antibody. This antibody reacts with the linear epitope E49YYLN53, which is
specific to class I pilins [3]. It was later recognized that the genomic location of the class I and II
pilin genes are also different [4, 5]. Type IV pili provide several properties to the bacteria: auto-
aggregation, adhesion to host cells, intracellular signaling, competence and a form of motility
called twitching motility [6]. The importance of this structure duringN. gonorrheae infection
has been demonstrated in human volunteers [7]. Male volunteers inoculated with a type IV pili
deficient strain only developed a watery urethral discharge or none at all. More recently, using
mice grafted with human skin, Melican et al. showed that type IV pili mediated adhesion of N.
meningitidis is a determining factor in vascular damage observed during purpura fulminans [8].
As a countermeasure against this virulence factor the immune system produces antibodies
against type IV pili [9]. The efficacy of N.meningitidis to proliferate in the throat and in blood
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during productive infection thus depends on its ability to evade type IV pili specific antibodies.
The amino acid sequence of class I pilins can vary by a process called antigenic variation [10].
Beside the expression locus of the major pilins a variable number of non-expressed (silent) pilS
loci with different but homologous sequences are present in Neisseria spp. genomes. Pilin anti-
genic variation results from a gene conversion, which transfers DNA from the silent cassettes
to the expression locus. Thus, the pilin sequence can change generating multiple different anti-
gens. Surprisingly, it was recently recognized that pilins belonging to class II lack this antigenic
variation in Neisseria meningitidis [11, 12]. Strains with sequence invariable pilE genes are fre-
quently isolated worldwide independently of serogroup, year or country of isolation [5]. Inter-
estingly class II pilin genes are restricted to certain clonal complexes, and all pilin genes from
clonal complexes cc1, cc5, cc8, cc11 and cc174 are class II. Importantly, these clonal complexes
display among the highest disease to carriage ratio, in other words they are hypervirulent [13].
Another interesting feature of these clonal complexes is the association with epidemic menin-
gococcal disease (cc1, cc5 and cc11). Countries in the “meningitis belt” in sub-Saharan Africa
have the highest burden of meningococcal disease with both large seasonal epidemics, and
much higher incidence rates compared to other areas of the world where outbreaks are small
and sporadic. These studies therefore raise the question of how, in absence of primary structure
variation, do class II expressing strains evade immunity targeted against type IV pili?
Another potential source of surface variation is post translational modification and in par-
ticular glycosylation. Pilin glycosylation has been identified in strains expressing class I pilins
that display a single glycosylation site on Ser63 [14–17] but has never been studied in class II
pilin expressing strains. Importantly, genes involved in the glycosylation of surface structures
(pgl genes) are submitted to phase variation. As a consequence, oligosaccharides present on the
bacterial surface vary between strains and change for one strain during the course of nasophar-
ynx colonization and infection. The Neisseria spp. glycosylation pathway starts with the synthe-
sis of an undecaprenyl diphosphate (Undpp) monosaccharide in the cytoplasm. Three
enzymes are involved in this step, PglB, C and D. In strains expressing the pglB1 allele these
enzymes synthesize an undecaprenyl-DATDH (diacetamido trideoxyhexose) and in strains
expressing the pglB2 allele a GATDH (glyceramido trideoxyhexose) core [18]. The Unpp-
monosaccharide can then be modified with additional sugars by three glycosyltransferases
pglH, pglA and pglE, the latter two being submitted to phase variation. When in the ON-phase,
pglA leads to the addition of a galactosyl residue on GATDH or DATDH [19]. PglH adds a gly-
cosyl residue on the same site [20]. Recently a pglH2 allele was described whose product adds
an N-acetyl glucosamine residue on the first sugar [21]. When a disaccharide is formed a third
sugar can be added by the PglE transferase. PglF is then responsible for the translocation of this
structure to the periplasmic side of the inner membrane [22]. Finally, the PglO/L oligosaccha-
ride transferase adds the sugar chain onto the pilin [23, 24].
Given the clinical importance of strains expressing class II pilins and the invariable nature
of their sequences, we decided to explore how such strains could evade immunity directed
against type IV pili. Since pilin glycosylation is a potential source of surface structure variation
we determined the nature of class II pilin glycosylation and show that this could provide
immune escape in the absence of primary structure variation.
Results
The class II pilin from the FAM20 strain displays multiple glycosylation
sites
The prototypical strain expressing a class II pilin is the FAM18 strain that was isolated from
the cerebrospinal fluid of a patient in North Carolina USA in the 1980s. Its genome has been
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sequenced and is publicly available [25]. We used a Nalidixic acid resistant variant of this strain
called FAM20 to characterize the posttranslational modifications of this representative class II
pilin [26]. Type IV pili were purified and characterized using a combination of high-resolution
mass profiling and top-down mass spectrometry [27].
Mass profiling of the FAM20 strain produced an exceptionally complex spectrum with over
20 different proteoforms [28] clearly distinguishable (Fig 1A, FAM20). Pilin masses ranged
from 15967 Da to over 16850 Da while the molecular mass predicted from the genome is only
14524 Da strongly indicating that numerous post translational modifications (PTMs) were
present. Pilin sequences from individual clones were identical indicating that differences in
mass were not due to recombination at the pilin locus as expected from previous studies [12].
In order to identify the different PTMs on this pilin we proceeded to simplify the spectral pat-
tern using specific mutants deficient for genes involved in PTMs. Certain proteoforms of the
FAM20 major pilin were separated by 124 Da suggesting that phosphoethanolamine (PE) was
present. As pptA is responsible for PE modification a pptA deletion mutant was generated (Fig
1A, pptA) and type IV pili were purified from this strain [29, 30]. The overall pattern of pilin
purified from the FAM20pptA strain was shifted towards lower masses and the number of
major proteoforms was reduced to about 12. Peaks with differences of mass corresponding to
one hexose were also frequently observed in the spectra (162 Da). Since FAM18 PglH was
found to add a glucose residue onto DATDH (glycosyl transferase) we generated and tested a
pglHmutant [20]. The complexity of the spectrum obtained with the pglH strain was also
greatly reduced confirming the activity of this enzyme (Fig 1A, pglH). To combine the effects
of each mutation a double mutant was made. The pglHpptA double mutant generated pili with
only 3 major proteoforms (15693, 15967 and 16241 Da). Strikingly, the mass difference
between the 3 peaks corresponded to one GATDHmoiety (274 Da, Fig 1, pglHpptA). This
result is a strong indication that the FAM20 pilin is glycosylated at least at 3 sites in contrast
with previously analyzed strains that showed only one glycosylation site [18, 23].
The reduced complexity of the pptApglH double mutant allowed us to identify the PTMs
found on the 3 proteoforms using top-down mass spectrometry (Fig 1B, S1 Fig and S1 Table).
Different charge states corresponding to each proteoform were submitted to Electron Transfer
Dissociation (ETD) fragmentation. As expected, the 3 proteoforms were found to be modified
with the usual pilin modifications: N-terminal methylation, disulfide bond between the two
cysteine residues and two phosphoglycerol moieties on Ser69 and Ser97 (Table 1). Proteoform 1
displayed two glycosylation sites with GATDH at Ser63 and Ser90. Proteoform 2 harbored three
glycosylation sites at Ser63, Ser87 and Ser98. Proteoform 3 harbored a fourth glycosylation site at
Ser90 in addition to those found on proteoform 2. The FAM20 strain can therefore harbor up
to 4 different glycans on the same pilin monomer. This detailed top-down analysis of the
mutant strain allowed us to precisely assign specific PTMs to the 23 different proteoforms
found in the wild type FAM20 highlighting the tremendous diversity of structures found on
the pilin of this strain (Fig 2).
The presence of multiple glycosylation sites is a common feature of
strains expressing class II pilins
The presence of a strikingly high number of pilin glycosylation sites in FAM20 raised the ques-
tion of whether this is a particularity of FAM20 or a common feature of strains expressing class
II pilins. We therefore collected several class II pilin expressing strains, isolated during a 2003–
2006 period from patients suffering from sepsis and meningitis at the Limoges university hos-
pital in France and analyzed their PTM (Table 2). Strains were selected to be part of different
serogroups and sequence types to represent a diverse panel with the common feature of
Multisite Glycosylation of Class II N.meningitidis Pilins
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Fig 1. Analysis of the posttranslational modifications of the class II pilin expressing strain FAM20. (A) Whole protein analysis of type IV pili prepared
from the FAM20 strain and mutants of the same strain pptA, pglH and the double mutant pglHpptA. (B) Top-down fragmentation maps of the three main
proteoforms found in the FAM20pglHpptA strain showing identified PTMs localized to sites on the PilE primary structure.
doi:10.1371/journal.ppat.1005162.g001
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expressing class II pilins. To allow detailed genetic analysis the entire genomic sequence of two
of these clinical strains was established and genes involved in pilin production and its glycosyl-
ation characterized (Fig 3A and 3B, LIM534 and LIM707). In both cases sequences of the
major pilin are closely related to the FAM20 type II sequence (S2 Fig) and the pilin gene is also
located between the katA and prlC genes as expected for class II expressing strains (Fig 3A).
Type IV pili were purified from these strains and submitted to high resolution intact mass pro-
filing. Overall, spectra were less complex than the FAM20 strain with 3–6 major proteoforms
(Fig 3C). Nevertheless pilin purified from LIM534, LIM712, LIM675 and LIM707, consistently
displayed evidence of multiple glycosylation sites (Fig 3C). The difference in mass between
major proteoforms could be explained by the sequential addition of several DATDH/GATDH
or DATDH-Hex/GATDH-Hex glycans depending on the strain. Top-down MS analysis of
Table 1. Measured neutral monoisotopic masses of PilE proteoforms from the FAM20pglHpptA double mutant and comparison with theoretical
masses calculated from the FAM20 sequence plus indicated PTMs.
FAM20 pglHpptA
proteoform
Measured monoisotopic neutral Mass
(Da)
Theoretical mass
(Da)
Error
(ppm)
PTM present*
1 15693.0104 15692.8603 9.6 Methylated N-ter, C-C, 2 PG, 2
GATDH
2 15967.0251 15966.9768 3.0 Methylated N-ter, C-C, 2 PG, 3
GATDH
3 16241.1870 16241.0933 5.8 Methylated N-ter, C-C, 2 PG, 4
GATDH
* C-C, disulﬁde bond; PG, phosphoglycerol; GATDH, glyceramido trideoxyhexose
doi:10.1371/journal.ppat.1005162.t001
Fig 2. Complete description of the 23 proteoforms expressed by the FAM20 strain.
doi:10.1371/journal.ppat.1005162.g002
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these different proteoforms demonstrated that proteoforms contained 2–5 glycosylation sites
(Fig 3D). These results show that strains expressing class II pilins from different clonal com-
plexes isolated from different continents and in different time periods share the common fea-
ture of carrying multiple glycosylation sites. This strongly suggests that such multisite pilin
glycosylation is a general feature of class II expressing strains.
The number of glycosylation sites is determined by the pilin primary
structure
The observation that class II pilin-carrying strains bear multiple glycosylation sites as opposed
to class I strains that carry only one, could be explained by two non-exclusive hypotheses. First,
the particular primary structure of class II pilins may itself be more favorable to glycosylation
due to a larger number of accessible serine residues. Second, this difference is due to the genetic
background and in particular to the pgl genes expressed by these strains.
As a first attempt to address this question the genomic regions carrying the pgl genes were
analyzed in two of the isolated class II pilin expressing strains, LIM534 and LIM707 but this
did not reveal any obvious explanation for the number of glycosylation sites. For instance, the
PglO/L oligosaccharide transferase was highly conserved between the class I (8013) and class II
(FAM18, LIM534 and LIM707) pilin-expressing strains with identity scores between 98 and
100%. As in the class I pilin-expressing strains the pglBCDFH genes are localized between the
ribD and avtA genes apart from the pglA and pglE genes which are located on a separate region
(Fig 3B). The LIM707 strain carries a split pglB2 gene (GATDH) previously found to maintain
functionality and an insertion containing orf2 and pglH between the pglF and pglB genes [20,
31]. The LIM534 strain expresses a pglB1 (DATDH) gene and displays an insertion containing
the orf2 and pglH genes but, interestingly, the pglH gene is interrupted by a transposase
explaining why only a monosaccharide is found on the pilin.
To address the potential role of the pilin sequence in determining the number of glycosyla-
tion sites we generated two “class swap”mutant strains, the first with a class II pilin in a class I
pilin-expressing genetic background and the reciprocal strain with a class I pilin in a class II
background. In the first case, a class II LIM707 pilin was expressed in the context of the 8013
background (8013pilELIM707, Fig 4A). Pilin from the 8013 strain normally harbors GATDH
at a single glycosylation site [18]. Expression of the class II LIM707 pilin in the 8013 back-
ground strain led to a pilin modified with up to 3 GATDHmoieties (Fig 4B and 4C). The gly-
cosylation sites were the same as in the original LIM707 strain. This result indicates that the pgl
genes from the 8013 strain are capable of modifying the pilin at multiple sites and that the
number of glycosylation sites is determined by the pilin sequence itself rather than the pgl
genes. To confirm this result the reverse situation was generated and the 8013 pilin (class I)
Table 2. Clinical isolates used in this study.
Strain Isolation Date Pilin Class CC* Serogroup Reference
8013 Blood 1989 I ST-18 C [58]
FAM20 CSF 1980s II ST-11 C [26]
LIM534 Throat 2006 II ST-5 A [27]
LIM712 Blood 2005 II ST- 11 C This study
LIM675 Blood 2003 II ST-11 C This study
LIM707 CSF 2003 II ST-11 C This study
*CC, clonal complex
doi:10.1371/journal.ppat.1005162.t002
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Fig 3. Genomic and biochemical description of class II pilin expressing strains isolated at different sites and at different times. (A) Genetic
organization of the pilin locus in the 8013, FAM20, LIM707, and LIM534 strains. (B) Genetic organization of the core pgl locus in the same strains. (C) High
resolution intact protein mass profiling of 4 class II pilin expressing strains demonstrating multisite glycosylation. (D) Alignment of the pilin sequences from
collected class II pilin expressing clinical strains. Sequences of theN.meningitidis 8013 and FAM20 strains and the N. gonorrhoeaeMS11 strain [35] are
included for reference. Glycosylation sites irrespective of their nature appear as black hexagons.
doi:10.1371/journal.ppat.1005162.g003
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was expressed in the FAM20 background (FAM20pilE8013, Fig 4D). High resolution MS anal-
ysis showed that pilins purified from this strain comprised of a more complex array of proteo-
forms due to modification with PE, PC, di and trisaccharides but the vast majority contained a
single glycosylation site at Ser63 (Fig 4E and 4F). Interestingly, in this case about 10% of the
pilin also contained a second glycosylation. Taken together these results show that the genetic
environment of the strain determines the type of sugar added, DATDH or GATDH, mono, di
Fig 4. Roles of pilin amino-acid sequence and genetic environment in determining the number of glycosylation sites. (A) Schematic representation
of the genetic modification introduced in the 8013 strain to express the class II pilin from the LIM707 strain (8013pilE707). (B) Whole protein mass
spectrometry analysis of the 8013pilE707 strain. (C) Distribution of the number of glycans per monomer in the 8013, 8013pilE707 and LIM707 strains. (D)
Schematic representation of the insertion introduced in the FAM20 strain to express the class I pilin from the 8013 strain (FAM20pilE8013). (E) Whole protein
mass spectrometry analysis of the FAM20pilE8013 strain. In this case there are multiple proteoforms harboring one glycosylation site. This is due to different
phosphoform content and the presence of either di or monosaccharide on Ser63. (F) Distribution of the number of glycans per monomer in the FAM20,
FAM20pilE8013 and 8013 strains. For panels D and F, average and standard deviations are indicated from 3 independent pili preparations.
doi:10.1371/journal.ppat.1005162.g004
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or trisaccharide but the presence of multiple glycosylation sites in class II pilins is largely deter-
mined by the primary structure of this class of pilins.
Multiple glycosylation sites on class II pilins affect type IV function in a
strain-specific fashion
Neisseria meningitidis class I pilin glycosylation has been shown to contribute to adhesion by
interacting with the platelet activating factor (PAF) receptor on the surface of human airway
cells [32]. In contrast, in Neisseria gonorrhoeae strains deficient for pilin glycosylation exhibited
an early hyper-adhesive phenotype but were attenuated in their ability to invade primary cervi-
cal epithelial cells [33]. The multiple glycosylation sites found on the class II pilins raised the
question of their function more acutely. To explore the function of glycosylation FAM20,
LIM707, LIM534 and 8013 strains deleted for the pglC and pglD genes were generated. Surpris-
ingly, however, despite repeated attempts we were unable to purify pili from the FAM20pglC
and FAM20pglD strains. Electron microscopy observation showed that these two strains do
not display any type IV pili on their surface (S2 Fig). Complementation of mutant strains with
the corresponding genes restored piliation. In the case of the FAM20 strain, glycosylation
appears to be necessary for efficient pilus assembly. This result was unique to the FAM20 strain
as the other two class II pilin expressing strains showed normal piliation in absence of
glycosylation.
The impact of the loss of glycosylation on the typical pilus properties of adhesion to endo-
thelial cells and auto-aggregation was then determined (Fig 5A–5D). As expected from the
absence of pili, the FAM20pglD strain showed very low adhesive capacity indistinguishable
from the non-piliated mutant (Fig 5A). In contrast, adhesion by the LIM707, LIM534 and 8013
strains were unaffected by the absence of pilin glycosylation. Similar results were found on pul-
monary epithelial cells (S3 Fig). Bacterial aggregation was evaluated as a second type IV pilus-
dependent property (Fig 5B–5D). As expected, the FAM20pglC and pglDmutants did not
show any aggregation. Bacterial aggregation of LIM534 and LIM707 was higher in the absence
of glycosylation. Interestingly, instead of being spherical, bacterial aggregates formed by the
unglycosylated LIM707 and LIM534 strains displayed unusual heterogeneous shapes. Such an
aggregation phenotype characterized by more aggregation and polymorphous aggregates is
reminiscent of strains deficient for the PilT retraction ATPase [34]. To evaluate whether the
absence of glycosylation was altering pilus retraction the motility of these strains was evaluated
(S4 Fig). Twitching motility depends on cycles of pilus extension and retraction that drag the
bacteria on a surface. The glycosylation mutants of the LIM534 and LIM707 strains did not
show any defect in motility indicating normal retraction on individual bacteria (S4 Fig). This
suggests that class II pilin glycosylation destabilizes pilus-pilus contacts allowing for dynamic
interactions between pili in the context of aggregates.
Taken together these results show that the absence of glycosylation on class II pilins leads to
strong functional changes, and such changes vary depending on the strain. In the most dra-
matic situation pili were not expressed on the surface. In other cases, pilus-pilus interactions
were stabilized leading to enhanced aggregation.
Modeling pili structures with multiple glycosylations reveals extensive
pilus surface coverage
The important functional impact of the multisite glycosylation displayed by class II pilins
described above suggests that sugars occupy a large percentage of the pilus surface. To explore
this hypothesis the structures of pilin fibers were modeled using the N. gonorrhoeaeMS11 pilin
as a template [35] and taking into account glycan PTM. Three glycans per monomer were
Multisite Glycosylation of Class II N.meningitidis Pilins
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Fig 5. Functional consequences of absence of glycosylation in class II strains. (A) Impact of class II pilin glycosylation on adhesion to endothelial cells.
Strains 8013, LIM707, LIM534, FAM20 and their corresponding pglDmutants were allowed to adhere to endothelial cells for 4 hours and the number of
adherent bacteria analyzed. A non-piliated pilDmutant of the 8013 strain was used as a negative control. (B-D) Quantitative and qualitative impact of pilin
glycosylation on bacterial aggregation in three class II pilin-harboring strains: (B) FAM20, (C) LIM707 and (D) LIM534. Bacteria were allowed to aggregate in
suspension and the size and number of aggregates determined using fluorescence microscopy following DAPI staining. The scale bar indicates 200 μm.
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included in the model as it represents the dominant and average proteoform. Pilus assembly
was performed as previously described [36] and corresponding sugars were built by energy
minimization and added onto the pilus fiber. Organization of the whole structure was then
refined first in vacuo and then in water. Glycosylated pilus structures formed of class II pilins
consistently show global coverage of the fibers by sugars (Fig 6A). Higher magnification of the
FAM20 pilus glycosylated on 3 sites per monomer, the most abundant proteoform, shows
extensive coverage of the pilus surface (Fig 6B). Glycosylation therefore strongly changes the
structure of the pilus fiber.
These results also suggest that glycosylation will perturb antibody recognition of the pilus
fibers. In particular, antibodies directed against the pilus structures would have limited direct
access to the protein backbone. As this could compensate for the absence of sequence variation
in the class II pilins we decided to investigate this point further. All atoms of the pilus in cylin-
dric coordinates were projected on a plane according to their height and angular coordinate, in
order to obtain a flat representation of the pilus surface on a 2D grid (Fig 6C). The surface at
the tip of antibodies, typically involved in antigen binding, is roughly circular in shape with a
diameter in the order of 5 nm. Since interaction with the antigen does not require the whole
surface we approximated the antibody-antigen binding site by using a 2 nm diameter disc [37].
The disc was tested against each position along a grid covering the pilus surface and for each
position the presence of sugar was evaluated. The percentage of positions where antibody bind-
ing was not affected by sugars was then determined (Fig 6D). For the 8013 class I expressing
strain that displays a single glycosylation site the presence of sugars decreased antibody accessi-
bility to 65% of the surface. In the case of the class II pilins that carry multiple glycosylation
sites, antibody accessibility was reduced to 15%, 11% and 9% of the surface in the FAM20,
LIM534 and LIM707 strains respectively. These results show that the surface-accessible amino-
acid residues of class II pilins are largely masked by glycosylation sites.
Discussion
Our results show that, unlike in class I pilins, a large portion of the pilus surface is coated with
sugars in class II pilins. Over the years pilin glycosylation of class I pilins has been studied from
3 different Neisseria meningitidis strains demonstrating a single conserved glycosylation site at
Ser63 (Table 3). Strain C311#3 displays a Gal(β1–4)Gal(α1–3)2,4-DATDH [16], strain 8013
one GATDH residue [14] and NIID280 a DATDH residue [17]. In addition, N. gonorrhoeae
strain N400 presents a hexose residue linked to a DATDH on its class I pilin also at Ser63 [15].
In this single study using top-down mass spectrometry, we describe for the first time the glyco-
sylation pattern of 5 different strains expressing class II pilins including the FAM18 reference
strain. Pilins from all of these 5 strains display 3 to 5 glycosylation sites (Table 3). Indepen-
dently of the serogroup, clonal complex, geographic site or temporal period of isolation of the
strains (Table 2), class I pilins show a single site of glycosylation while class II pilins have multi-
ple sites of glycosylation.
Molecular modeling reveals that multisite glycosylation of the pilin monomer leads to the
coverage of the pilus surface. This could have important consequences in terms of adaptation
of the bacteria to the host immune response. More specifically, this could explain why amino-
acid sequence variation is not required in class II strains because the polypeptide chain is not
exposed to the extracellular milieu and thus not submitted to pressure by the immune system.
That is not to say that antibodies cannot recognize glycosylated class II pilins: indeed
Mean ± standard deviation was determined and indicated on the figures. Statistical analysis was done by paired two-tailed t-test; * indicates P 0.05; **
indicates P 0.01.
doi:10.1371/journal.ppat.1005162.g005
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Fig 6. Molecular modeling of antibody accessibility to the primary structure of class II pilins. (A) Overall aspect of the glycosylated pilus fibers from the
8013, FAM20, LIM534 and LIM707 strains. The polypeptide structure appears in cyan and the surface representation of the sugars appears in color. (B)
Detailed view of the FAM20 fiber formed with the proteoform with three glycosylation sites. Sugars appear in purple. (C) Projection of the pilus surface on a
2D grid. The antigen-binding tip of an antibody is represented at the same scale. Sugar moieties appear in black. (D) Antibody accessibility to the polypeptide
chain in the presence or absence of sugar modifications. Results are presented as the percentage of positions along the grid that allow a 2 nm disc to be
placed on the pilus surface without touching sugar moieties relative to all positions on the grid.
doi:10.1371/journal.ppat.1005162.g006
Multisite Glycosylation of Class II N.meningitidis Pilins
PLOS Pathogens | DOI:10.1371/journal.ppat.1005162 September 14, 2015 13 / 24
glycopeptides from type IV pili are immunogenic [38, 39]. Rather, these results suggest that the
immune escape scenario would then be different between class I and II pilins. In the case of
class I pilins, after throat colonization by a given strain the IgAs specific for the pilin primary
sequence will be produced and lead to killing of the initial strain, but variants arising from
recombination at the pilin genetic locus will survive until a second adaptation of the immune
system. This cycle can potentially repeat itself numerous times. In the case of class II strains the
primary structure is cloaked in oligosaccharides, and only antibodies targeted to epitopes that
include sugar moieties will efficiently lead to bacterial killing. In this case variants in the sugar
structure will survive. Type IV pili have been considered as potential vaccine antigens against
Neisseria gonorrhoeae infections but sequence variation in class I pilins has hampered these
attempts [40, 41]. In the absence of sequence variation in class II pilins it could be tempting to
use such proteins as vaccine antigens but our results show that glycosylation would complicate
this approach.
A number of arguments support the idea that sugar structure does change during infection
of individuals and during epidemics. It has been shown that sera from infected patients during
acute and convalescent stage meningococcal disease recognize the major pilin [9] and thus
establishes that type IV pili are indeed a target of the immune system and its pressure. It is also
well documented that certain pgl genes such as pglA and pglE are submitted to phase variation
[42]. This implies that the functionality of these genes and thus the nature of pilin glycosylation
can vary at rates between 10−2 to 10−6 per cell per generation giving the bacteria the opportu-
nity to evade antibody response against type IV pili [43, 44]. Beyond phase variation, pgl genes
appear to be the site of rapid changes including at the epidemic scale. Lamelas et al. performed
a longitudinal study in Northern Ghana between 2001 and 2009 [45] where they collected and
sequenced the genomes of 100 strains in order to identify evolutionary changes during these
epidemic waves. This revealed that the pgl genes were the site of no less than 5 successive
recombination events during this period. Importantly, all of the strains in this study display
class II pilins (Gerd Pluschke, personal communication). Our work also provides evidence of
changes in pilin glycosylation. In the case of the LIM534 strain the pglH gene is interrupted by
an insertion sequence. This insertion event is a molecular signature of changes in the nature of
the sugars coating a class II pilin. Taken together these studies underline the high level of varia-
tion undergone by class II pilin glycosylation likely to evade the immune response directed
against pili.
Our results also provide an explanation for the molecular mechanism that leads to multisite
glycosylation in class II pilins. We showed that expression of a class II pilin in a strain normally
expressing a class I pilin leads to glycosylation on multiple sites on the pilin backbone. This
Table 3. Summary of the number of glycosylation sites found in the differentNeisseria meningitidis
strains.
Strain Pilin class Number of sites Reference
C311 I 1 [16]
8013 I 1 [14]
NIID280 I 1 [17]
N400 I 1 [15]
FAM20 II 4 This study
LIM534 II 5 This study
LIM712 II 4 This study
LIM675 II 4 This study
LIM707 II 4 This study
doi:10.1371/journal.ppat.1005162.t003
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result shows that the pilin amino-acid sequence is a determining factor for multisite glycosyla-
tion. Alignment of the pilin sequences from class I and II strains suggests two scenarios. Cer-
tain glycosylated serines present on class II pilins are simply absent in class I pilins (e.g. serines
at alignment positions 88, 91 or 118 in class II are absent in class I). Alternatively the serine is
present on class I pilins but the local sequence is different (e.g. serines at alignment position 68
and 99) and this would likely affect glycosyltransferase recognition. Predominance of pilin
sequence in the determination of glycosylation sites is confirmed by the reciprocal situation.
When a class I sequence is expressed in the class II expressing background, the vast majority of
the pilin contains only one sugar. It is noteworthy however that the genetic background, and
most probably the pgl genes, also plays a partial role in determining the number of glycosyla-
tion sites. Indeed, when the class II pilin is expressed in its normal background the main pro-
teoform contains 3 glycans per monomer whereas when it is expressed in the class I expressing
background the main proteoform contains only 2. Furthermore, when the class I sequence is
expressed in the class II expressing background the main proteoform contains one sugar but
10% of pilins also contain 2 sugars. It is therefore likely that pilins of different classes have co-
evolved with their respective pgl systems and the glycosylation systems in class II pilin express-
ing strains are more efficient.
Independently of the number of glycosylation sites, the nature of the sugars on the pilin is
determined by the pgl genes. The FAM20 strain expresses a pglB2 allele, pglA and pglE genes
are in the OFF phase and the insertion with the ORF2 and pglH genes is present. Accordingly,
pilins from this strain are modified with a GATDH core, determined by the pglB2 allele, and
between 1 and 2 hexose residues likely being a glucose transferred by PglH. Interestingly, the
PglH transferase expressed by this strain is partially functional in the sense that certain sites
display a GATDH-hexose while others a GATDHmonosaccharide. This specificity of the pglH
allele contributes to the complexity of the pattern found on pilins expressed by the FAM20
strain. The LIM707 strain contains the same expression pattern of pgl genes as the FAM20
(pglB2 allele, pglAOFF, pglEOFF, pglH present) leading to the production of a GATDH-Hexose
type of sugar. In contrast to the FAM20 strain, all sugars on the LIM707 pilin are disaccharides.
For the LIM534 strain, we observe the pglB1 allele, pglA and pglE alleles are in the OFF phase
and the pglH gene is present but interrupted by an insertion sequence. In this case, only
DATDH is present as predicted by the genomic data. When pilin sequences are introduced
into a different genetic background the nature of sugar changes with the genetic background of
the strain. When the pilin gene from the LIM707 strain is introduced in the 8013 background,
the pilin becomes modified with a GATDH residue as found in the 8013 strain rather than
with a GATDH-Hexose disaccharide. Similarly, introduction of the 8013 pilin gene into the
FAM20 strain leads to the expression of pilin modified with GATDH-hexose. Overall these
results show that the pilin sequence determines the number of glycosylation sites and the pgl
gene pattern the nature of the sugar.
An intriguing result of this study is the difference in functional consequence of the lack of
glycosylation in the different class II pilin expressing strains. The most striking phenotype is in
the FAM20 strain where type IV pili are simply not expressed on the surface of the bacteria in
absence of glycosylation. This phenotype is specific to the FAM20 strain as the LIM707 or
LIM534 strains still adhere to host cells via their type IV pili despite inactivation of the pgl
genes. Another specificity of the FAM20 strain is the high number of proteoforms expressed.
In addition to the 2–4 glycosylation sites displayed by this strain, phosphoglycerol (2) phos-
phoethanolamine (1–3) and phosphocholine (2) modifications are also present. It is possible
that in absence of sugar these numerous modifications generate a specific structural environ-
ment that is incompatible with pilus expression. It is also possible that the piliation machinery
has co-evolved with the glycosylation of this strain and that specific interactions with the
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machinery such as with the PilQ secretin require glycosylation. Further work is required to elu-
cidate at which step glycosylation is necessary for piliation in the FAM20 strain. For instance,
identification of the point at which pilus biogenesis is blocked in the FAM20pglC/D strains will
yield useful information to understand the mechanisms of pilus biogenesis. A role for glycosyl-
ation in the assembly and function of pili in other organisms has been described. In Neisseria
gonorrhoeae, pilin (class I) glycosylation has subtle effects on pilus dynamics [46]. Perhaps a
similar but more prevalent mechanism is at play in the FAM20 strain. Glycosylation of the
Pseudomonas aeruginosamajor pilin is also necessary for efficient piliation [47]. In Archea, the
archaellum, a swimming organelle closely related to type IV pili bears glycosylation sites that
are required for assembly [48]
Surprisingly, in strains LIM707 and LIM534 absence of glycosylation of their class II pilins
did not affect adhesion to either endothelial or epithelial cells. This is in contrast with previous
studies on strains expressing class I pillins that reported a decrease of adhesion in strains lack-
ing pilin glycosylation due to direct interactions of the sugars with cellular receptors [33].
Recently, the recombinant non-glycosylated class I pilin from the 8013 strain was shown to
interact with the surface protein CD147 [49]. In principle class II pilins could mediate interac-
tions with cellular receptors through the polypeptidic chain but modeling shows that its acces-
sibility is limited by the numerous surface exposed glycans. Intriguingly, our results thus make
a direct interaction between the major pilin and a cellular receptor difficult to imagine at the
structural level. Further structural work is required to clarify this point. In contrast, the absence
of glycosylation of the pilins expressed by LIM707 and LIM534 led to enhanced aggregation
and to an unusual aggregation behavior likely due to stabilized pilus-pilus interactions. These
results are consistent with the idea that multisite class II pilin glycosylation leads to changes in
surface properties of type IV pili. These results also point out that the functional consequences
of pilin glycosylation could be different in class I and class II pilins.
Overall, our work revises the current view of pilin glycosylation. Starting from a single mod-
ification per pilin in class I strains we now realize that a large proportion of N.meningitidis
strains express class II pilins and carry multiple glycosylation sites. Our study first reveals the
profound implications in terms of pilus biogenesis, structure and function. The results pre-
sented here also have important implications in terms of immunity against type IV pili, vaccine
design and how N.meningitidismanages to escape the immune system. In particular the pres-
ence of multiple glycosylation sites provides a simple explanation for the absence of pilin
sequence variation in class II pilins and suggests that variations in sugar structure are the main
motor for immune evasion in these strains. The worldwide distribution, hypervirulence and
association with epidemic forms of the disease of strains carrying class II pilins underscore the
importance of these results to understand Neisseria meningitidis infections. In the more global
context of infectious diseases our study highlights the wealth of strategies exploited by patho-
gens to escape the immune system and the key role played by glycosylation.
Materials and Methods
Bacterial strains and growth conditions
N.meningitidis strains were grown on GC agar base plates (Conda Laboratorios, Spain) con-
taining Kellogg's supplements [7] and, when required, 5 μg/ml chloramphenicol at 37°C in
moist atmosphere containing 5% CO2. Escherichia coli transformants were grown in liquid or
solid Luria-Bertani medium (Difco) containing 100 μg/ml ampicillin. Neisseria meningitidis
strains used in this study are described in Table 4.
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Molecular biology techniques
Genomic sequencing of clinical strains. Genomic sequencing of the LIM534 and LIM707
strains was performed with an Illumina sequencer with 2x74 paired-end sequences. Sequencing
was performed at the sequencing platform IMAGIF (Centre de Recherche de Gif– www.imagif.
CNRS.fr). Sequences were then assembled with the CLC Genomics Workbench 7 software
using the assembly tool and submitted to the BIGSdb (http://pubmlst.org/software/database/
bigsdb/).
Gene inactivation. Mutations in the pptB, pptA and pglD genes were described elsewhere
[36]. To delete the pglH gene, an upstream region amplified with PglH-NF and PglH-NR prim-
ers (Table 5) and a downstream region amplified with PglH-CF and PglH-CR primers were
restricted by the corresponding enzymes and ligated in the pBluescript plasmid restricted with
SalI and SacI (Stratagene), then the kanamycin resistance cassette was cloned in the BamHI
site.
Allelic exchange. The megaprimer strategy [50] was used to substitute the type II pilin
sequence from the LIM707 strain into the 8013 strain normally expressing a class I pilin
(8013pilE707). The first amplification was done using E707-F and E707-R primers using geno-
mic DNA from the LIM707 strain as a template. The amplicon was used as a megaprimer to
amplify the TopoPCR2.1 vector containing the 8013 pilin sequence followed by a kanamicyn
resistance cassette [51]. Amplification products were treated with DpnI and transformed into
E. coli. Plasmids from resulting clones were sequenced to identify those carrying the LIM707
pilin sequence. A positive plasmid was selected for transformation into the 8013 strain.
To introduce the 8013 pilE and pilS loci into FAM20, first the lxpC to pilE fragment was
amplified from 8013 chromosomal DNA using the primers 8013-lpxC-pilE_FWD and
8013-lpxC-pilE_REV. and cloned into the plasmid pBlunt (Life Technologies). The ermC resis-
tance gene was cloned downstream of pilE into the PmeI site. This construct was transformed
into 8013 selecting for ErmR and the adjacent DNA sequenced. Chromosomal DNA from the
ErmR 8013 was used to transform FAM20 selecting for ErmR, and transformants were
screened by PCR using primers McPilRBS and3-end-ErmR_FWD to identify transformants
that had recombined the pilE gene along with ermC. These transformants were further ana-
lyzed using primers Mid_pilEandS1FWD, Late_pilEandS1FWD, 3’end_pilS1 FWD,
5’end_fkbP REV, 3’end_pilS5 REV, 3end8013REVpilS1, 3end8013FORpilS1,
Table 4. Genetically modified strains used in this study.
Strain Genotype Reference
8013pglC 8013ΔpglC::mariner [59]
8013pglD 8013ΔpglD::mariner [59]
FAM20pglH FAM20ΔpglH::alphA-3 This study
FAM20pptA FAM20ΔpptA::mariner This study
FAM20pglHpptA FAM20ΔpglH::cat ΔpptA::mariner This study
FAM20pglC FAM20ΔpglC::mariner This study
FAM20pglD FAM20ΔpglD::mariner This study
LIM707pglC LIM707ΔpglC::mariner This study
LIM707pglD LIM707ΔpglD::mariner This study
LIM534pglC LIM534ΔpglC::mariner This study
LIM534pglD LIM534ΔpglD::mariner This study
FAM20pilE8013 FAM20 ΔpilE::pilE8013 This study
8013pilE707 8013 ΔpilE::pilE707 This study
doi:10.1371/journal.ppat.1005162.t004
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3end8013REVpilS2, and 428bp_pre-pilS1 and long PCR conditions (LongAmp Taq, NEB) to
identify transformants carrying the entire pilS locus from 8013. DNA sequence analysis of PCR
products was performed to confirm the presence of all 8013 sequences between lpxC and fkbP
in FAM20.
The FAM20 native, class II pilE locus was cloned by amplifying the FAM20 pilE using prim-
ers FAM20-pilE_FWD and FAM18-pilE_REV and cloning into pSMART HC Amp (Lucigen).
After confirmation by sequence analysis, plasmid DNA was treated with EZ-Tn5<KAN-2>
(Epicenter) and the mini-transposon insertion site identified by PCR as 95 bp downstream of
the translation start site. This construct was then transformed in the FAM20 strain to interrupt
the endogenous pilE gene and to generate the FAM20pilE8013 strain.
Mass spectrometry techniques
PilE preparation. Pili were prepared as described previously [36]. Briefly, bacteria from
10–12 Petri dishes were harvested in 5 mL of 150 mM ethanolamine at pH 10.5. Pili were
sheared by vortexing for 1 min. Bacteria were centrifuged at 4,000xg for 30 min at 4°C and the
resulting supernatant further centrifuged at 15,000 x g, 30 min, ambient temperature. The
supernatant was removed, pili precipitated from the suspension by the addition of 10% (vol/
vol) ammonium sulfate saturated in 150 mM ethanolamine pH 10.5 and allowed to stand for 1
h. The precipitate was pelleted by centrifugation at 4,000xg for 1 h at 20°C. Pellets were washed
twice with PBS and suspended in 100 μL distilled water.
Table 5. Oligonucleotides used in this study.
Primer Sequence* Enz.
pglHNF2 GTCGACGGAATTTCATTTCCGGAAAAC SalI
pglHNR GGATCCAGCAATAAGGGGCGACGATG BamHI
pglHCF GGATCCAAGTTGCCGAAGTCCTTAC BamHI
pglHCR GAGCTCACCGCCAGATTGAAAATGC SacI
E707F GAGGCATTTCCTTTCCAATTAGGAGTAATTTTATGAAAGCAATCCAAAAAGGTTTC
E707R CCATTTATTATTTCCTTCCTCTTTTCTGATCCTTACTTATTTGGTGCGGCAGGTAGA
8013-lpxC-pilE_FWD GCCGTCTGAAGCGTCGGGCAAATCATCGC
8013-lpxC-pilE_REV GATTGTGATTGCCATCGTCG
FAM20-pilE_FWD gccgtctgaaATTTGGTGCGGCAGGTAG
FAM20-pilE_REV AGGTTTCACCCTGATCGAG
McPilRBS gcatttcctttccaattaggag
3-end-ErmR_FWD cgttatgaaatgggttaaca
Mid_pilEandS1FWD GTCAGCAGTGCCGAAAATTGTCAG
Late_pilEandS1FWD CCTCGTCGGTGCAGAAACTTA
3’end_pilS1 FWD ctcggtgacggctgatttttgac
5’END_FKBP REV gctgaaagtgtacgaataaAGC
3’END_PILS5 REV CTGACATAAtggcttcaag
3END8013REVPILS1 CATCCTTTTGGTCgaaggtc
3END8013FORPILS1 gaccttcGACCAAAAGGATG
3END8013REVPILS2 GACGAAGCTATCCTTttggccg
428BP_PRE-PILS1 FOR CATCGGTACGGAAACTTATCG
FAM18-PILE_FWD gccgtctgaaATTTGGTGCGGCAGGTAG
FAM18-PILE_REV AGGTTTCACCCTGATCGAG
* Restriction sites in bold
doi:10.1371/journal.ppat.1005162.t005
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High resolution mass profiling. Protein samples were desalted by C4 ZipTip (Millipore)
and eluted directly into a 10 μL spray solution of methanol:water:formic acid (75:25:3). A small
amount, 2–6 μL, was introduced into either an Orbitrap Velos mass spectrometer, equipped
with ETD module (Thermo Fisher Scientific, Bremen, Germany) or Orbitrap Fusion mass
spectrometer (Thermo Scientific, San Jose CA) using a TriVersa NanoMate (Advion Biosci-
ences, Ithaca, NY, USA) in positive ion mode. The spray voltage was set to 1.2–1.6 kV and
back-pressure to 0.3–0.4 psi. A full set of automated positive ion calibrations was performed
immediately prior to mass measurement.
For Orbitrap Velos MS the transfer capillary temperature was lowered to 100°C, sheath and
auxiliary gasses switched off and source transfer parameters optimised using the auto tune fea-
ture. Helium was used as the collision gas in the linear ion trap. The FT automatic gain control
(AGC) was set at 1x106 for MS experiments. Spectra were acquired in the FTMS in full profile
mode with between 1 and 20 microscans over several minutes, with averaging on and set to the
maximum value, and a resolution of 60,000 atm/z 400. The final few spectra were then aver-
aged using Qualbrowser in Thermo Xcalibur 2.1 and deconvoluted using Xtract to produce
zero charge mass spectra.
For Orbitrap Fusion MS transfer capillary temperature was lowered to 100°C, sheath and
auxiliary gasses switched off and protein mode switched on. The pressure in the ion routing
multiple was lowered to 4 mTorr and ions detected directly in the Orbitrap. Spectra were
acquired at resolutions of 120,000 atm/z 200 with between 1 and 20 microscans over several
minutes with averaging. Processing was performed as for spectra acquired with the Orbitrap
Velos.
Top-down mass spectrometry & data analysis. For top-down MS/MS experiments per-
formed on the Orbitrap Velos the FT automatic gain control (AGC) was set at 2x105. Ions cor-
responding to the isotopic distribution of a single charge state were selected with the largest
possible window to avoid overlap with neighbouring species but minimize signal loss. ETD was
performed using fluoranthene as the reagent gas. Interaction times were varied to maximise
sequence coverage but were kept below 20 ms. Supplemental activation was used as noted.
Spectra were acquired in the FTMS in full profile mode at a resolution of 60,000 at m/z 400,
with between 10 and 50 microscans and with averaging on and set to the maximum value. The
final few spectra were then averaged using Qualbrowser in Thermo Xcalibur 2.1 and deconvo-
luted using Xtract to produce singly charged MS/MS spectra.
Top-down experiments on the Orbitrap Fusion were done in a similar way with ion selec-
tion performed in the quadrupole, ETD performed in the linear ion trap at interaction times of
3–10 ms and fragment ions detected in the Orbitrap at high resolution.
Peak list data resulting from the deconvolution of several spectra (often different charge
states of the same species or ETD experiments performed on the same charge state but with dif-
ferent interaction times) were combined and imported into a home built package for ion
assignment and automated fragmentation map creation. Low mass, low charge ions that are
often clearly present in the spectra but missed by the Xtract algorithm were added manually to
the list and PTM assignment was performed with this software tool.
Functional assays
Bacterial aggregation assay. Bacteria grown on GCB agar plates were adjusted to OD600
of 0.05 and incubated for 2 hours at 37°C in RPMI containing 10% FBS. The bacterial suspen-
sion was concentrated to OD600 of 0.3 by centrifugation at 15000 x g for 1 min followed by
resuspension in medium containing DAPI (4’, 6- diamidino-2-phenylindol; 0.1 μg/ml). Bacte-
rial suspensions were briefly vortexed and transferred in a glass-bottom 96-well plate (Ibidi
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GmbH, München, Germany). After a 30 min incubation step, aggregates were observed micro-
scopically with a 4x lens and size and numbers of bacteria involved in aggregates relative to the
total amount of bacteria were determined with the ImageJ software, as previously described
[36].
Bacterial adhesion assay. Adhesion of meningococci to human umbilical vein endothelial
cells (HUVECs) was done as described previously [52]. Cells were grown at 37°C in a humidi-
fied incubator under 5% CO2. HUVECs (Promo- Cell, Heidelberg, Germany) were used
between passages 1 and 8 and grown in Endo-SFM (Gibco) supplemented with 10% heat-inac-
tivated fetal bovine serum (FBS, PAA Laboratories GmbH, Pasching, Austria) and endothelial
cell growth supplement (Harbor Bioproducts, Norwood, USA). Monolayers of 105 cells in
24-well plates were infected with 107 bacteria (MOI of 100). The inoculum was characterized
by CFU counts. After 30 min, unbound bacteria were removed by three washes and the infec-
tion was continued for 4h. Finally, after 3 washes adherent bacteria were recovered by scraping
the wells and counted by plating appropriate dilutions on GCB agar plates.
Adhesion of meningococci to the human epithelial cell line A549 was performed as
described for HUVECs except that a MOI of 500 was used instead of 100. A459 cells were a gift
from Prof. Claire Poyart (Institut Cochin, Paris), cultured in DMEM high glucose, GlutaMAX,
pyruvate (Life-Technologies) supplemented with 10% heat-inactivated FBS and maintained at
37°C and 5%CO2 in a humidified incubator.
Twitching motility assay. Twitching motility assays of N.meningitidis were performed
inside a flow chamber (Ibidi GmbH, München, Germany). Bacteria (2.5x107) were introduced
into the flow chamber and incubated for 30 min at 37°C. Unbound bacteria were removed by 3
washes. Bacterial motility was monitored by video microscopy over a 2-minute period with the
acquisition of 2 frames per second. Cell tracking was then analyzed with the ImageJ software
using the spot tracking plug-in (http://icy.bioimageanalysis.org). Velocities of single bacterial
tracks were calculated in time intervals of 2 s.
Molecular modeling
Homology modeling. Target sequences were aligned to the MS11 N. gonorrhoeae pilin
sequence, which shares high sequence identity with our strains: 77%, 56%, 59% and 59% for
8013, LIM534, LIM707 and FAM20, respectively. Individual pilin were modeled with Modeller
9v8 [53], using unmodified amino-acids sequences. The N. gonorrhoeae pilin structure (PDB
code 2HIL) was used as template. 500 homology models were built with the standard proce-
dure, clustered with the MMTSB Tool Set (www.mmtsb.org), and the best structure was
selected according to the Dope assessment score [54], in the most populated cluster.
Pilus modeling. The approach for building the pilus was adapted from the multi-stage
procedure described by Chamot-Rooke et al. [36]. We used CNS [55] with a modified version
of the CHARMM19 force field, which included hand-made topology and parameters for the
glycosylated sites (DATDH, GATDH, GATDH-Hex). The helical properties of the pili were
taken from the N. Gonorrhoeae structure (rise 10.5 Å, angle 105.5°) and enforced throughout
the modeling using the NCS STRICT command in CNS. In this way, only one unit is explicitly
modeled with 20 virtual neighbors. First, we built the structures of the glycosylated sites by
quick minimization with a simplified non-bonded interaction (repulsive Van der Waals only).
The rest of the pilin was kept rigid during this stage. The second stage was a refinement in
vacuo of the whole pilin, using adapted non-bonded parameters [36]. The third stage was a
refinement in water, similar to the one used in NMR structure determination [56]. During the
second and the third stage, the initial structures were maintained in a flexible and adaptive way
using log-harmonic distance restraints and automated weighting [57].
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Supporting Information
S1 Fig. Top-down analysis of the glycosylation sites present on the three main proteoforms
of the FAM20pglHpptA strain. For each proteoform 3 panels describe: (A) A representative
top-down ETDMS/MS Orbitrap spectrum that has been performed on a single charge state of
PilE; (B) shows the full fragmentation maps resulting from PTM assignment for individual
experiments perform on single charge states of each proteoform and (C) The combined full
fragmentation map from all experiments in panel B. Details of the assigned ions can be found
in S1 Table.
(TIF)
S2 Fig. Transmission electron microscopy of negatively stained bacteria as previously
described [36]. (A) LIM707; (B) LIM707pglD; (C) LIM354; (D) LIM534pglD; (E) FAM20; and
(F) FAM20pglD.
(TIF)
S3 Fig. Impact of pilin glycosylation on adhesion to human epithelial cells. Strains 8013,
LIM707, LIM 534 and their corresponding pglDmutants were allowed to adhere to A549
human epithelial cells for 4 hours and the number of adherent bacteria analyzed. A non-
piliated pilDmutant of the 8013 strain was used as a negative control. Average and standard
deviations are indicated from three independent experiments.
(TIF)
S4 Fig. Twitching motility in absence of glycosylation in the class II pilin expressing
strains.
(TIF)
S1 Table. c/z fragment ions of the three proteoforms found in the FAM20pglHpptA strain.
(XLSX)
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